CNTB•benzinga•
Connect Biopharma Announces Week 12 Top-Line Results From Phase 2 CBP-307 Trial In Patients With Moderate-To-Severe Ulcerative Colitis; Says 'intends to engage in partnership discussions for future development of CBP-307 to focus on lead program CBP-201'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga